Abstract
Peyronie's disease can best be described as a localized connective tissue disorder that primarily affects the tunica albuginea of the penis. The disease may be attributed to repetitive vascular trauma that initiates an inflammatory process and ultimately leads to the formation of a fibrous penile plaque. The plaque consists mainly of collagen and can significantly alter penile anatomy and function. Patients with Peyronie's disease will most often present with penile curvature, pain on erection, a palpable nodule most commonly located on the dorsal shaft of the penis, and erectile dysfunction. There is no definitive treatment for Peyronie's disease and the treating physician has many options. They may wait for spontaneous resolution of the plaque, choose medical therapy (which includes both oral and intralesional regimens), or opt for surgical management. The main purpose of this article is to discuss the advances in medical therapy for Peyronie's disease, in particular intralesional injection of interferon-alpha-2b (IFN-α-2b). Several studies have concluded that IFN-α-2b can be an effective modality of treatment and that many patients placed on a regimen of IFN-α-2b experienced a significant reduction in penile curvature, diminished pain with erection, and decreased size of the plaque. Further clinical studies are currently being undertaken to determine the precise quantity and frequency of administration of IFN-α-2b that is most effective with the least amount of side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carson CC . Francoix Gigot de la Peyronie Invest Urol 1981 19: 62–63
Levine LA . Peyronie's disease: a difficult sexual dysfunction problem West J Med 1998 169: 168–169
Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease J Urol 1990 144: 1376–1379
Carson CC . Peyronie's disease: medical and surgical management In: Hellstrom WJG, ed Handbook of sexual dysfunction American Society of Andrology: San Francisco 1999 pp 93–98
Scardino PL, Scott WW . The use of tocopherols in the treatment of Peyronie's disease Ann NY Acad Sci 1949 52: 390–401
Yudkin JS . Peyronie's disease in association with metoprolol Lancet 1977 2: 1355
Van de Berg JS et al. Mechanisms in calcification in Peyronie's disease J Urol 1982 127: 52–56
Somers KD, Winters PA, Dawson DM . Chromosomal abnormalities in Peyronie's disease J Urol 1987 137: 672–676
Jarow JP, Lowe FC . Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction J Urol 1997 158: 1388–1390
Levine LA . Treatment of Peyronie's disease with intralesional verapamil injection J Urol 1997 158: 1395–1399
Chilton CP, Castle WM, Westwood CA, Pryor JP . Factors associated in the etiology of Peyronie's disease Br J Urol 1982 54: 748–750
Nyberg LM, Bias WB, Hochberg MC, Walsh PC . Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens J Urol 1982 128: 48–51
Hellstrom WJG, Bivalacqua TJ . Peyronie's disease: etiology, medical, and surgical therapy J Androl 2000 21: 347–354
Roddy TR, Goldstein I, Devine CJ . Peyronie's disease, part I Am Urol Assoc Update Ser 1991 10: 1
Hacshe-Klunder R . Treatment of Peyronie's disease using para-aminobenzoate potassium (Potaba), para-aminobenzoic acid potassium Urologe 1978 17: 224–227
Ralph DJ, Brooks MD, Botazzi GF . The treatment of Peyronie's disease with tamoxifen Br J Urol 1992 70: 648–661
Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study Urology 1994 44: 291–295
Gelbard MK, Lindner A, Kaufman JJ . The use of collagenase in the treatment of Peyronie's disease J Urol 1985 134: 280–283
Gelbard MK, James K, Riach P, Dorey F . Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study J Urol 1993 149: 56–58
Levine LA, Merrick PE, Lee RC . Intralesional verapamil injection for the treatment of Peyronie's disease J Urol 1994 151: 1522–1524
Rehman J, Benet A, Melman A . Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study Urology 1998 51: 620–626
Stuart-Harris RG, Lauchler R . The clinical application of the interferons: a review Med J Aust 1992 156: 869–872
Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta, and -gamma Scand J Urol Nephrol 1991 25: 89–94
Ahuja SK, Sikka SC, Hellstrom WJG . Stimulation of collagen production in an in vitro model for Peyronie's disease Int J Impot Res 1999 11: 207–212
Berman B, Duncan MR . Short-term keloid treatment in vivo with human interferon alpha 2b results in a selective and persistent normalization of keloid fibroblast collagen glycosaminoglycan, and collagenase production in vitro J Am Acad Dermatol 1989 21: 694–702
Benson RC, Knoll LD, Furlow WL . Interferon-alpha-2b in the treatment of Peyronie's disease J Urol 1991 145: 342A
Wegner HE, Andersen R, Knipsel HH, Miller K . Treatment of Peyronie's disease with local interferon-alpha-2b Eur Urol 1995 28: 236–240
Wegner HE, Andersen R, Knipsel HH, Miller K . Local interferon-alpha-2b is not an effective treatment in early stage Peyronie's disease Eur Urol 1997 32: 190–193
Judge IS, Widniewski ZS . Intralesional interferon in the treatment of Peyronie's disease: a pilot study Br J Urol 1997 79: 40–42
Ahuja S et al. A pilot study demonstrating clinical benefit from intralesional interferon-alpha-2b in the treatment of Peyronie's disease J Androl 1999 20: 444–448
Brake M, Loertzer H, Horsch R, Keller H . Treatment of Peyronie's disease with local interferon-alpha-2b Br J Urol 2001 87: 654–657
Novak TE et al. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease J LA State Med Soc 2001 153: 358–363
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lacy, G., Adams, D. & Hellstrom, W. Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. Int J Impot Res 14, 336–339 (2002). https://doi.org/10.1038/sj.ijir.3900867
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900867
Keywords
This article is cited by
-
Peyronie’s Disease: Intralesional Therapy and Surgical Intervention
Current Urology Reports (2016)